Singapore, Jan 12, 2012: Amerigen Pharmaceuticals and VIWA Pharmaceutical signed a memorandum of understanding (MOU) to establish a joint venture to develop and register a range of branded generic medicines for sale in China. It is anticipated that the products, once approved, would be manufactured at Amerigen's SFDA and US FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party. Mr Jonathan Embleton, Amerigen's chief business officer commented, "We look forward to working with VIWA to bring some first time and technically sophisticated generic products to Chinese patients at more affordable prices, without compromising on quality."

Mr Jack H Ye, VIWA's managing director, added, "Combining Amerigen's development capabilities, manufacturing assets and access to products from Western markets with VIWA's access to API's and regulatory expertise in China should enable the joint venture to rapidly build up its product portfolio. This in turn will help accelerate VIWA's strategic thrust into the commercialization of finished pharmaceutical products in China."

Mr John Lowry, Amerigen's president & CEO added, "The formation of this joint venture marks a first step by Amerigen to bring high quality and locally manufactured branded generic products to the Chinese market and, in the process, establish an Amerigen brand in China. We anticipate that additional collaborations will be established to further this strategy."